← Back to search results

cancelledFind a Tender · award

Drug Development Framework

Buyer: Cardiff University →

BuyerCardiff University
Statuscancelled
DeadlineNot published
ValueValue not published
Published19 Jan 2021

What is being bought

Cardiff University are ranked 2nd nationally for the impact of their research and are among the top five universities in the UK for research excellence. Cardiff University has a thriving and innovative research culture, with research that has real impact and makes a positive difference to the world. As part of this, the University is translating fundamental discoveries in disease processes to develop new medicines to meet unmet clinical needs. Cardiff University is looking for companies with an innovative outlook and recognised expertise in supporting drug-discovery projects from early screening (electrophysiology and in vitro DMPK) to delivering de-risked novel molecules to clinical trials. Successful companies will be committed to the principles of the NC3Rs and will add value to our work by providing high-quality data for informing the drug-discovery pipeline.

Delivery location

UKL22 · UKL22 · UKL22 · UKL22

Categories

Research laboratory services 73111000Research laboratory services 73111000

Lot details

Electrophysiology Services

We require providers for electrophysiology services relevant to neuroscience drug development. Currently we require validated ion channel assays for GABAA and NMDA modulators, on an automated electrophysiology platform, with QC and report generation. In the near future, it is likely we will require a range of other ion channel assays, as well as manual patch clamp services. We may also want to purchase ion channel expressing cell lines (under a MTA).

Statuscancelled

Award criteria
as per procurement docs — 100
price — 0

In-vivo assays

We require providers for in-vivo assays, most usually with oral administration. We currently require reliable assays for pro-cognitive and anxiolytic effects. In the future, we may require assays to demonstrate other drug modulated effects, such as, but not limited to, an anti-depressive effect.

Statuscancelled

Award criteria
as per procurement docs — 100
price — 0

In-vitro drug metabolism (ADME-Tox) services

We require providers of in-vitro drug metabolism (ADME-Tox) services as part of our drug development pipeline. This includes, but is not limited to, measures of metabolism, permeability and transporters, physicochemical properties, protein binding and toxicology.

Statuscancelled

Award criteria
as per procurement docs — 100
price — 0

In-vivo pharmacokinetics (PK) and toxicology

We require providers of in-vivo drug metabolism (ADME-Tox) services as part of our drug development pipeline.

Statuscancelled

Award criteria
as per procurement docs — 100
price — 0

What is included

ItemCategoryQuantity
1Research laboratory servicesNot published
2Research laboratory servicesNot published
3Research laboratory servicesNot published
4Research laboratory servicesNot published

Comparable-procurement analytics

Benchmarked against retained Find a Tender procedures with CPV division 73. The category anchor is Research laboratory services (73111000); this is a deliberately broad market comparator. The comparison is shown at several levels rather than pretending one company or region is always the best benchmark.

Comparison setProceduresReported bids per procedureNamed award suppliersPrice evidence
Market: CPV division 733,0453 median · 26.7 average (1,087 of 3,045 with a bid count)2.5 average (1,228 of 3,045 with named award suppliers)Not published
Same buyer51 median · 1 average (3 of 5 with a bid count)1 average (3 of 5 with named award suppliers)Not published
Delivery region: UKL22111 median · 1.5 average (6 of 11 with a bid count)1 average (7 of 11 with named award suppliers)Not published

“Reported bids” is an official aggregate, sometimes reported per lot; it is the closest available competition measure. “Named award suppliers” are winners, not all applicants.

Price-outcome signal

Not enough comparable procedures currently publish both a GBP tender value and a usable lowest-valid-bid value to calculate a responsible price-reduction benchmark. Tenderline deliberately does not infer a saving from named award suppliers or from missing award values.

Procurement strategy & market signals

Framework agreementNot published
Dynamic purchasing systemNot published
Competitive procurementNot published
Recurring requirementNot published
Procurement method rationaleNot published
Rationale classificationsNot published
Special regimeNot published
Covered byGPA
Submission policyNot published
Selection criteriaNot published
Risk detailsNot published

Planning & early market engagement

BudgetValue not published
No-engagement rationaleNot published
Planning documents0
Planning milestones0

No planning milestones published.

Related procurements

No linked framework, prior procurement or reprocurement published.

Awards

Electrophysiology Services

Statusunsuccessful

In-vivo assays

Statusunsuccessful

In-vitro drug metabolism (ADME-Tox) services

Statusunsuccessful

In-vivo pharmacokinetics (PK) and toxicology

Statusunsuccessful

Documents & submission route

No documents are published in the current source record.

Source data inventory

Diagnostic view. “Not published” means this current release does not provide a value.

OCIDocds-h6vhtk-028b65
Latest release ID001039-2021
Latest release timestampTue Jan 19 2021 10:24:02 GMT+0000 (Coordinated Universal Time)
Sourcefind-a-tender
Official notice URLNot published
Tender statuscancelled
Procurement methodopen
Procurement method detailsOpen procedure
Main procurement categoryservices
Above thresholdNot published
Legal basis32014L0024
Tender period: startNot published
Tender period: endNot published
Expression of interest deadlineNot published
Enquiry deadlineNot published
Award period: startNot published
Award period: endNot published
Submission method detailsNot published
Submission languagesNot published
Electronic catalogue policyNot published
Total tender valueNot published
Tender lots in source4
Tender items in source4
Tender documents in source0
Awards in latest release4
Contracts in latest release0
Parties in latest release3

Notice history

DateEventReference
19 Jan 2021award, contract001039-2021

All source data

Unmodified official OCDS data retained by Tenderline for this procurement process.

Complete current OCDS release JSON
{
  "id": "001039-2021",
  "tag": [
    "award",
    "contract"
  ],
  "date": "2021-01-19T10:24:02Z",
  "ocid": "ocds-h6vhtk-028b65",
  "buyer": {
    "id": "GB-FTS-1902",
    "name": "Cardiff University"
  },
  "links": [
    {
      "rel": "prev",
      "href": "https://ted.europa.eu/udl?uri=TED:NOTICE:177464-2020:TEXT:EN:HTML"
    }
  ],
  "awards": [
    {
      "id": "001039-2021-CU258-1",
      "title": "Electrophysiology Services",
      "status": "unsuccessful",
      "relatedLots": [
        "1"
      ],
      "statusDetails": "discontinued"
    },
    {
      "id": "001039-2021-CU258-2",
      "title": "In-vivo assays",
      "status": "unsuccessful",
      "relatedLots": [
        "2"
      ],
      "statusDetails": "discontinued"
    },
    {
      "id": "001039-2021-CU258-3",
      "title": "In-vitro drug metabolism (ADME-Tox) services",
      "status": "unsuccessful",
      "relatedLots": [
        "3"
      ],
      "statusDetails": "discontinued"
    },
    {
      "id": "001039-2021-CU258-4",
      "title": "In-vivo pharmacokinetics (PK) and toxicology",
      "status": "unsuccessful",
      "relatedLots": [
        "4"
      ],
      "statusDetails": "discontinued"
    }
  ],
  "tender": {
    "id": "CU258",
    "lots": [
      {
        "id": "1",
        "title": "Electrophysiology Services",
        "status": "cancelled",
        "hasOptions": false,
        "description": "We require providers for electrophysiology services relevant to neuroscience drug development.\nCurrently we require validated ion channel assays for GABAA and NMDA modulators, on an automated electrophysiology platform, with QC and report generation.\nIn the near future, it is likely we will require a range of other ion channel assays, as well as manual patch clamp services. We may also want to purchase ion channel expressing cell lines (under a MTA).",
        "awardCriteria": {
          "criteria": [
            {
              "name": "as per procurement docs",
              "type": "quality",
              "description": "100"
            },
            {
              "type": "price",
              "description": "0"
            }
          ]
        }
      },
      {
        "id": "2",
        "title": "In-vivo assays",
        "status": "cancelled",
        "hasOptions": false,
        "description": "We require providers for in-vivo assays, most usually with oral administration. We currently require reliable assays for pro-cognitive and anxiolytic effects. In the future, we may require assays to demonstrate other drug modulated effects, such as, but not limited to, an anti-depressive effect.",
        "awardCriteria": {
          "criteria": [
            {
              "name": "as per procurement docs",
              "type": "quality",
              "description": "100"
            },
            {
              "type": "price",
              "description": "0"
            }
          ]
        }
      },
      {
        "id": "3",
        "title": "In-vitro drug metabolism (ADME-Tox) services",
        "status": "cancelled",
        "hasOptions": false,
        "description": "We require providers of in-vitro drug metabolism (ADME-Tox) services as part of our drug development pipeline. This includes, but is not limited to, measures of metabolism, permeability and transporters, physicochemical properties, protein binding and toxicology.",
        "awardCriteria": {
          "criteria": [
            {
              "name": "as per procurement docs",
              "type": "quality",
              "description": "100"
            },
            {
              "type": "price",
              "description": "0"
            }
          ]
        }
      },
      {
        "id": "4",
        "title": "In-vivo pharmacokinetics (PK) and toxicology",
        "status": "cancelled",
        "hasOptions": false,
        "description": "We require providers of in-vivo drug metabolism (ADME-Tox) services as part of our drug development pipeline.",
        "awardCriteria": {
          "criteria": [
            {
              "name": "as per procurement docs",
              "type": "quality",
              "description": "100"
            },
            {
              "type": "price",
              "description": "0"
            }
          ]
        }
      }
    ],
    "items": [
      {
        "id": "1",
        "relatedLot": "1",
        "deliveryAddresses": [
          {
            "region": "UKL22"
          }
        ],
        "additionalClassifications": [
          {
            "id": "73111000",
            "scheme": "CPV",
            "description": "Research laboratory services"
          }
        ]
      },
      {
        "id": "2",
        "relatedLot": "2",
        "deliveryAddresses": [
          {
            "region": "UKL22"
          }
        ],
        "additionalClassifications": [
          {
            "id": "73111000",
            "scheme": "CPV",
            "description": "Research laboratory services"
          }
        ]
      },
      {
        "id": "3",
        "relatedLot": "3",
        "deliveryAddresses": [
          {
            "region": "UKL22"
          }
        ],
        "additionalClassifications": [
          {
            "id": "73111000",
            "scheme": "CPV",
            "description": "Research laboratory services"
          }
        ]
      },
      {
        "id": "4",
        "relatedLot": "4",
        "deliveryAddresses": [
          {
            "region": "UKL22"
          }
        ],
        "additionalClassifications": [
          {
            "id": "73111000",
            "scheme": "CPV",
            "description": "Research laboratory services"
          }
        ]
      }
    ],
    "title": "Drug Development Framework",
    "status": "cancelled",
    "coveredBy": [
      "GPA"
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "description": "Cardiff University are ranked 2nd nationally for the impact of their research and are among the top five universities in the UK for research excellence. Cardiff University has a thriving and innovative research culture, with research that has real impact and makes a positive difference to the world. As part of this, the University is translating fundamental discoveries in disease processes to develop new medicines to meet unmet clinical needs.\nCardiff University is looking for companies with an innovative outlook and recognised expertise in supporting drug-discovery projects from early screening (electrophysiology and in vitro DMPK) to delivering de-risked novel molecules to clinical trials. Successful companies will be committed to the principles of the NC3Rs and will add value to our work by providing high-quality data for informing the drug-discovery pipeline.",
    "classification": {
      "id": "73111000",
      "scheme": "CPV",
      "description": "Research laboratory services"
    },
    "procurementMethod": "open",
    "mainProcurementCategory": "services",
    "procurementMethodDetails": "Open procedure"
  },
  "parties": [
    {
      "id": "GB-FTS-1902",
      "name": "Cardiff University",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKL",
        "locality": "Cardiff",
        "postalCode": "CF24 0DE",
        "countryName": "United Kingdom",
        "streetAddress": "Procurement Services, McKenzie House, 30-36 Newport Road"
      },
      "details": {
        "url": "http://www.cardiff.ac.uk/business/why-work-with-us/for-suppliers",
        "buyerProfile": "https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0258",
        "classifications": [
          {
            "id": "BODY_PUBLIC",
            "scheme": "TED_CA_TYPE",
            "description": "Body governed by public law"
          },
          {
            "id": "09",
            "scheme": "COFOG",
            "description": "Education"
          }
        ]
      },
      "identifier": {
        "legalName": "Cardiff University"
      },
      "contactPoint": {
        "email": "Buyline@cardiff.ac.uk",
        "telephone": "+44 2920879648"
      }
    },
    {
      "id": "GB-FTS-172",
      "name": "European Union",
      "roles": [
        "funder"
      ]
    },
    {
      "id": "GB-FTS-111",
      "name": "High Court",
      "roles": [
        "reviewBody"
      ],
      "address": {
        "locality": "London",
        "postalCode": "WC2A 2LL",
        "countryName": "United Kingdom",
        "streetAddress": "Royal Courts of Justice, The Strand"
      },
      "identifier": {
        "legalName": "High Court"
      },
      "contactPoint": {
        "telephone": "+44 2079477501"
      }
    }
  ],
  "language": "en",
  "planning": {
    "budget": {
      "finance": [
        {
          "id": "1",
          "description": "Call-off contracts under this framework may be financed by EU funds",
          "relatedLots": [
            "1",
            "2",
            "3",
            "4"
          ],
          "financingParty": {
            "id": "GB-FTS-172",
            "name": "European Union"
          }
        }
      ]
    }
  },
  "description": "Bidders will need to create an account via In-Tend (https://in-tendhost.co.uk/cardiffuniversity/aspx/Home) in order to view the tender documents.\n(WA Ref:107445)",
  "initiationType": "tender"
}
Complete JSON history (1 releases)
19 Jan 2021 · 001039-2021 · award, contract
{
  "id": "001039-2021",
  "tag": [
    "award",
    "contract"
  ],
  "date": "2021-01-19T10:24:02Z",
  "ocid": "ocds-h6vhtk-028b65",
  "buyer": {
    "id": "GB-FTS-1902",
    "name": "Cardiff University"
  },
  "links": [
    {
      "rel": "prev",
      "href": "https://ted.europa.eu/udl?uri=TED:NOTICE:177464-2020:TEXT:EN:HTML"
    }
  ],
  "awards": [
    {
      "id": "001039-2021-CU258-1",
      "title": "Electrophysiology Services",
      "status": "unsuccessful",
      "relatedLots": [
        "1"
      ],
      "statusDetails": "discontinued"
    },
    {
      "id": "001039-2021-CU258-2",
      "title": "In-vivo assays",
      "status": "unsuccessful",
      "relatedLots": [
        "2"
      ],
      "statusDetails": "discontinued"
    },
    {
      "id": "001039-2021-CU258-3",
      "title": "In-vitro drug metabolism (ADME-Tox) services",
      "status": "unsuccessful",
      "relatedLots": [
        "3"
      ],
      "statusDetails": "discontinued"
    },
    {
      "id": "001039-2021-CU258-4",
      "title": "In-vivo pharmacokinetics (PK) and toxicology",
      "status": "unsuccessful",
      "relatedLots": [
        "4"
      ],
      "statusDetails": "discontinued"
    }
  ],
  "tender": {
    "id": "CU258",
    "lots": [
      {
        "id": "1",
        "title": "Electrophysiology Services",
        "status": "cancelled",
        "hasOptions": false,
        "description": "We require providers for electrophysiology services relevant to neuroscience drug development.\nCurrently we require validated ion channel assays for GABAA and NMDA modulators, on an automated electrophysiology platform, with QC and report generation.\nIn the near future, it is likely we will require a range of other ion channel assays, as well as manual patch clamp services. We may also want to purchase ion channel expressing cell lines (under a MTA).",
        "awardCriteria": {
          "criteria": [
            {
              "name": "as per procurement docs",
              "type": "quality",
              "description": "100"
            },
            {
              "type": "price",
              "description": "0"
            }
          ]
        }
      },
      {
        "id": "2",
        "title": "In-vivo assays",
        "status": "cancelled",
        "hasOptions": false,
        "description": "We require providers for in-vivo assays, most usually with oral administration. We currently require reliable assays for pro-cognitive and anxiolytic effects. In the future, we may require assays to demonstrate other drug modulated effects, such as, but not limited to, an anti-depressive effect.",
        "awardCriteria": {
          "criteria": [
            {
              "name": "as per procurement docs",
              "type": "quality",
              "description": "100"
            },
            {
              "type": "price",
              "description": "0"
            }
          ]
        }
      },
      {
        "id": "3",
        "title": "In-vitro drug metabolism (ADME-Tox) services",
        "status": "cancelled",
        "hasOptions": false,
        "description": "We require providers of in-vitro drug metabolism (ADME-Tox) services as part of our drug development pipeline. This includes, but is not limited to, measures of metabolism, permeability and transporters, physicochemical properties, protein binding and toxicology.",
        "awardCriteria": {
          "criteria": [
            {
              "name": "as per procurement docs",
              "type": "quality",
              "description": "100"
            },
            {
              "type": "price",
              "description": "0"
            }
          ]
        }
      },
      {
        "id": "4",
        "title": "In-vivo pharmacokinetics (PK) and toxicology",
        "status": "cancelled",
        "hasOptions": false,
        "description": "We require providers of in-vivo drug metabolism (ADME-Tox) services as part of our drug development pipeline.",
        "awardCriteria": {
          "criteria": [
            {
              "name": "as per procurement docs",
              "type": "quality",
              "description": "100"
            },
            {
              "type": "price",
              "description": "0"
            }
          ]
        }
      }
    ],
    "items": [
      {
        "id": "1",
        "relatedLot": "1",
        "deliveryAddresses": [
          {
            "region": "UKL22"
          }
        ],
        "additionalClassifications": [
          {
            "id": "73111000",
            "scheme": "CPV",
            "description": "Research laboratory services"
          }
        ]
      },
      {
        "id": "2",
        "relatedLot": "2",
        "deliveryAddresses": [
          {
            "region": "UKL22"
          }
        ],
        "additionalClassifications": [
          {
            "id": "73111000",
            "scheme": "CPV",
            "description": "Research laboratory services"
          }
        ]
      },
      {
        "id": "3",
        "relatedLot": "3",
        "deliveryAddresses": [
          {
            "region": "UKL22"
          }
        ],
        "additionalClassifications": [
          {
            "id": "73111000",
            "scheme": "CPV",
            "description": "Research laboratory services"
          }
        ]
      },
      {
        "id": "4",
        "relatedLot": "4",
        "deliveryAddresses": [
          {
            "region": "UKL22"
          }
        ],
        "additionalClassifications": [
          {
            "id": "73111000",
            "scheme": "CPV",
            "description": "Research laboratory services"
          }
        ]
      }
    ],
    "title": "Drug Development Framework",
    "status": "cancelled",
    "coveredBy": [
      "GPA"
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "description": "Cardiff University are ranked 2nd nationally for the impact of their research and are among the top five universities in the UK for research excellence. Cardiff University has a thriving and innovative research culture, with research that has real impact and makes a positive difference to the world. As part of this, the University is translating fundamental discoveries in disease processes to develop new medicines to meet unmet clinical needs.\nCardiff University is looking for companies with an innovative outlook and recognised expertise in supporting drug-discovery projects from early screening (electrophysiology and in vitro DMPK) to delivering de-risked novel molecules to clinical trials. Successful companies will be committed to the principles of the NC3Rs and will add value to our work by providing high-quality data for informing the drug-discovery pipeline.",
    "classification": {
      "id": "73111000",
      "scheme": "CPV",
      "description": "Research laboratory services"
    },
    "procurementMethod": "open",
    "mainProcurementCategory": "services",
    "procurementMethodDetails": "Open procedure"
  },
  "parties": [
    {
      "id": "GB-FTS-1902",
      "name": "Cardiff University",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKL",
        "locality": "Cardiff",
        "postalCode": "CF24 0DE",
        "countryName": "United Kingdom",
        "streetAddress": "Procurement Services, McKenzie House, 30-36 Newport Road"
      },
      "details": {
        "url": "http://www.cardiff.ac.uk/business/why-work-with-us/for-suppliers",
        "buyerProfile": "https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0258",
        "classifications": [
          {
            "id": "BODY_PUBLIC",
            "scheme": "TED_CA_TYPE",
            "description": "Body governed by public law"
          },
          {
            "id": "09",
            "scheme": "COFOG",
            "description": "Education"
          }
        ]
      },
      "identifier": {
        "legalName": "Cardiff University"
      },
      "contactPoint": {
        "email": "Buyline@cardiff.ac.uk",
        "telephone": "+44 2920879648"
      }
    },
    {
      "id": "GB-FTS-172",
      "name": "European Union",
      "roles": [
        "funder"
      ]
    },
    {
      "id": "GB-FTS-111",
      "name": "High Court",
      "roles": [
        "reviewBody"
      ],
      "address": {
        "locality": "London",
        "postalCode": "WC2A 2LL",
        "countryName": "United Kingdom",
        "streetAddress": "Royal Courts of Justice, The Strand"
      },
      "identifier": {
        "legalName": "High Court"
      },
      "contactPoint": {
        "telephone": "+44 2079477501"
      }
    }
  ],
  "language": "en",
  "planning": {
    "budget": {
      "finance": [
        {
          "id": "1",
          "description": "Call-off contracts under this framework may be financed by EU funds",
          "relatedLots": [
            "1",
            "2",
            "3",
            "4"
          ],
          "financingParty": {
            "id": "GB-FTS-172",
            "name": "European Union"
          }
        }
      ]
    }
  },
  "description": "Bidders will need to create an account via In-Tend (https://in-tendhost.co.uk/cardiffuniversity/aspx/Home) in order to view the tender documents.\n(WA Ref:107445)",
  "initiationType": "tender"
}